BioCentury
ARTICLE | Top Story

GW soars after Epidiolex meets Phase III endpoint

March 15, 2016 1:06 AM UTC

GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH) said Epidiolex cannabidiol met the primary endpoint of significantly reducing convulsive seizures vs. placebo in a Phase III trial to treat Dravet syndrome, a rare form of epilepsy. GW gained 302.5p (140%) to 519p in London and rose $46.25 (120%) to $84.71 on NASDAQ on Monday.

Epidiolex led to a median reduction in monthly convulsive seizures in the 14-week treatment period of 39% from baseline, compared with 13% for placebo (p=0.01). Patients had a median of 13 convulsive seizures per month at baseline, as measured during a four-week observation period. ...